NCT03841292 - Using Non-invasive Brain Stimulation (tDCS) With Varenicline for Treating Tobacco Dependence | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions

Tobacco DependenceSmoking CessationTobacco SmokingTobacco Use DisorderSubstance Use DisordersMolecular Mechanisms of Pharmacological ActionPhysiological Effects of Drugs

Interventions

DRUG

Varenicline

Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).

DEVICE

Active tDCS

Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session

DEVICE

Sham tDCS

Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.

Trial Locations (1)

M5T1P7

Centre for Addiction and Mental Health, Toronto

All Listed Sponsors

lead

Centre for Addiction and Mental Health

OTHER